Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2506

miR-17-92 as targets and agents for cardiac regeneration

Inventors: Dazhi Wang, Jinghai Chen

Invention Types: Therapeutics

Research Areas: Cardiovascular/Cardiology

Keywords: Cell Therapy, Heart Disease

For More Information Contact:  Miracco, Amy

 

Invention Description:

Cardiomyocytes in adult mammalian hearts are terminally differentiated and lack the capacity to regenerate. Death of cardiomyocytes are primary causes of heart failure and mortality. An ability to regenerate heart tissues could bring a valuable new treatment for patients. |


Dr. Da Zhi Wang and Dr. Jinghai Chen identified miR-17-92 as a critical regulator of cardiomyocyte proliferation. The researchers found that overexpression of miR-17-92 induces cardiomyocyte proliferation in embryonic, postnatal, and adult hearts. They identified that miR-19, in particular, is required for and sufficient to induce cardiomyocyte proliferation in vitro, and in vivo experiments are underway to further validate the initial results. The researchers also identified PTEN, a tumor suppressor, as a miR-17-92 target to mediate the function of miR-17-92 in cardiomyocyte proliferation.

Applications:

These studies suggest that miR-17-92 cluster have the potential to be therapeutic targets and agents for cardiac repair and heart regeneration.

Competitive Advantages:

Death of mature cardiomyocytes in pathological cardiac conditions and the lack of regeneration capacity of adult hearts are primary causes of heart failure and mortality. miR-17-92 is required for cardiomyocyte proliferation in the heart.
|

miR-17-92 induces cardiomyocyte proliferation in embryonic, postnatal and adult hearts, and it’s over expression protects the heart from myocardial infarction-induced injury.

Business Opportunity:

Exclusive license or sponsored research

Key Publications: Chen J, et al. mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ Res. 2013 Jun 7;112(12):1557-66.

IPStatus: Patented